Real-world effectiveness and persistence of golimumab as second-line anti-TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO-BEYOND, a 12-month prospective observational study.
D'Angelo S, Tirri E, Giardino AM, De Rosa T, Matucci-Cerinic M, Dagna L, Santo L, Ciccia F, Frediani B, Govoni M, Pallavicini FB, Grembiale RD, Sedie AD, Mulè R, Cantatore FP, Foti R, Gremese E, Conigliaro P, Salaffi F, Viapiana O, Cauli A, Giacomelli R, Arcarese L, Guggino G, Russo R, Puenpatom A, Capocotta D, Nacci F, Anelli MG, Picerno V, Binetti C, Iannone F; GO-BEYOND Italy Study Investigators.
D'Angelo S, et al. Among authors: capocotta d.
Int J Rheum Dis. 2024 Mar;27(3):e15091. doi: 10.1111/1756-185X.15091.
Int J Rheum Dis. 2024.
PMID: 38433479
No abstract available.